Drug Use Evaluation: Smoking Cessation
|
|
- Nigel O’Brien’
- 6 years ago
- Views:
Transcription
1 Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon Phone Fax Drug Use Evaluation: Smoking Cessation Tobacco cessation products cost the United States $193 billion each year in health care costs and lost productivity. An estimated 14% of Medicaid costs are attributable to tobacco use. In 2006, approximately 35% of Medicaid recipients smoked cigarettes. Tobacco dependence treatments (including FDA-approved pharmacotherapy, individual, group and telephone counseling) are highly cost-effective, even cost-saving in some populations. Oregon is the only state that covers all tobacco cessation treatments recommended by the federal clinical practice guidelines. 1 About 21% of Americans currently smoke cigarettes. Cigarette smoking is the leading cause of death in America. Deaths from tobacco related illnesses number 440,000+ yearly and have not declined in the past few years. 1 According to the Surgeon General, on average, men who smoke cut their lives short by 13.2 years, and female smokers lose 14.5 years. It costs the U.S. $75 billion in direct medical costs and $82 billion in lost productivity. 2 Tobacco Cessation Seventy percent (45.3 million) of U.S. smokers have reported that they want to quit smoking and 44.2% (19.9 million) attempt to quit every year; however, only about 7% become tobacco-free without professional help. 3 For patients motivated to quit smoking, abstinence is the goal. To aid in this endpoint, both non-pharmacotherapy and pharmacotherapy interventions play a role. Fiore, et al, found non-pharmacologic interventions, including individual counseling, group counseling and extra treatment social support helped increase nicotine abstinence rates, even in the absence of pharmacologic treatment, but found quit rates highest when counseling and pharmacotherapy are combined. 4 Evidence supported physician advice as well as interventions lasting up to 3 minutes significantly increased long-term abstinence rates. Behavioral therapies of extended duration in terms of session length, total contact time, and number of sessions were found to be more effective than briefer encounters. There was strong evidence that sessions lasting 10 minutes, and attendance to 4 or more sessions was strongly identified with cessation efficacy. 4 Bentz published research which show MD office counseling >10 minutes, interactive telephone counseling along with pharmacotherapy, and group counseling with pharmacotherapy can increase 1 year abstinence rates up to 10%, 25% and 35% respectively. 5 Others have published results which show, with good smoking cessation programs, 20 to 40 percents of participants are able to quit smoking for up to 1 year. 6 Tobacco cessation has many positive benefits. Stroke is reduced to that of a person who never smoked after 5-15 years of not smoking; cancers of the mouth, throat, and esophagus risks are halved 5 years after quitting. Coronary heart disease risk is cut by half 1 year after quitting and is nearly the same as someone who never smoked 15 years after quitting. Lung cancer risk drops by as much as half 10 years after quitting. Cervical cancer risk, peripheral artery disease, ulcer risk, COPD risk are all reduced after quitting, and bladder cancer risk is halved a few years after quitting. Low birth weight baby risk drops to normal if pregnant women quit before pregnancy or during their first trimester. 7 Male smokers who quit between ages add an average of 5 years to their lives. Female quitters in this age group add 3 years. Men and women who quit at ages increase their life expectancy by 1 year. 6 Telephone counseling: Proactive telephone counseling was found efficacious in assisting people to quit smoking. One case study found smokers are four times as likely to use quitlines as face-to-face clinics, given the same promotional effort. 8 Multiple studies have looked at abstinence success rates with proactive telephone counseling via quit-lines. All studies with multiple calls (at least one call with one follow-up, up to 6 call backs from the quit-line counselor) increased abstinence rates at 3 months and decreased relapse rates at 1 year. In one large meta-analysis, the younger patients, being male, and the lighter smoker did significantly better at sustaining abstinence rates with proactive telephone counseling. 9 Every state has access to a tobacco quit line and there is evidence that these quit lines are effective as an additional resource for smokers motivated to quit. Only 1% of patients use their states' quit-lines according to a recent survey of state/province quit-line use across the United States and Canada. 10
2 Hollis J, et al, conducted a randomized trial of 4614 Oregon tobacco callers and compared brief (one 15 minute call), moderate (one 30 minute call and a follow-up call) and intensive (five proactive calls) intervention protocols, with or without offers of free nicotine patches (NRT). Blinded staff assessed tobacco use by phone at 12 months. They found abstinence odd ratios were significant for moderate and intensive intervention especially when NRT was also offered. They concluded that offering free NRT and multi-session telephone support led to higher quit rates, and similar costs per incremental quit, than less intensive protocols. 11 The Oregon Tobacco Quit Line (ORQL) is a free statewide phone-based tobacco treatment program. Services include a one-call program (Help Line Call), and a multi-call program through the Free & Clear Quit For Life Program. The onecall may consist of any or all of the following: phone counseling with a Quit Coach, referrals to community resources, written educational material, and information on potential services offered through the callers' insurance. The multi-call program is an intensive proactive treatment that provides up to four follow-up calls, written stage-based educational material, referrals to community resources and additional caller-initiated Quit Line support. Provision of tobacco cessation medications (nicotine patch and gum) are also offered based on the tobacco user's health insurance status and medication use exclusion status. According to the Oregon Tobacco Quit Line Evaluation Report, Year 09, evaluation of an assessment of callers' satisfaction with the ORQL services as well as their tobacco use and/or abstinence showed about 30% of quit-line users were quit at the time of the survey. Continued tobacco users reported a high interest in quitting in the future and demonstrated successful reductions in smoking. 49.4% of the smokers who weren't quit at the follow-up evaluation had reduced the amount of cigarettes smoked compared to their initial (baseline) amount, and 13.6% reduced the amount of cigarettes by 20 cigarettes. Of those who were still smoking at follow-up, almost 80% reported a strong desire to quit. 12 Medication available Nicotine patches (NRT), Bupropion, and Varenicline (Chantix) are used as first line agents in cessation therapy. Nicotine products (gum, lozenge, spray, inhaler) are often used as rescue agents. Nortriptyline and Clonidine have also been used as second line agents in tobacco cessation. This review focuses on varenicline and defining its place in therapy. Varenicline (Chantix R ) Varenicline blocks the nicotine receptors and increases dopamine release which disrupts the reinforcing effects of nicotine and compensates for withdrawal symptoms. There are 5 published studies using varenicline vs. placebo, and three of these studies also included comparisons between varenicline and bupropion. All studies showed varenicline was significantly more efficacious than placebo for short term and long-term abstinence. Pooled odds ratio (OR) for continuous abstinence at 12 months for varenicline vs. placebo was 3.22 across these studies. Varenicline quit rate averaged 21.4% vs. control quit rate of 8%. 13 When compared to Bupropion, varenicline had higher abstinence rates at 12 weeks, and 1 year in one study, 14 while another study showed a non-significant higher rate for varenicline at 1 year. 15 Pooled OR of quit rates for varenicline vs. bupropion was 1.66, in favor of varenicline. 13 A trial by Tonstad, et al, using 24 weeks of varenicline was superior to 12 weeks for purposes of maintaining smoking abstinence. The first 12 weeks was open label, and only those who were abstinent after this time went on for the next 12 weeks. For weeks the quit rates were 43.6% for varenicline and 36.9% for placebo. 16 By eliminating those who failed to quit in the open label part, the authors essentially eliminated around 1/3 of individuals who varenicline was not effective for, so relapse prevention rates are higher than one would see in the real world. 17 Counseling was offered in all the studies, all had numerous inclusion and exclusion criteria, plus significant drop-outs due to adverse reactions. Varenicline was associated with significant nausea (30% average) and abnormal dreams across the studies. 13 Varenicline had higher abstinence rates when compared to nicotine patch at the end of treatment and a non-statistically greater rate at 1 year. 18 Varenicline did statistically reduce craving, withdrawal symptoms and smoking satisfaction compared to NRT at the end of treatment. 18 The FDA issued an alert in February 2008, highlighting important revisions to the warnings and precautions sections of the full prescribing information for varenicline, regarding serious neuropsychiatric symptoms. These symptoms include changes in behavior, agitation, depressed mood, suicidal ideation, and attempted and completed suicide. In most cases, neuropsychiatric symptoms developed during varenicline treatment, but in others, symptoms developed following withdrawal of varenicline therapy and even occur before the patient has discontinued smoking. The direct role of varenicline in these reported cases is not clear because smoking cessation, with or without treatment, is associated with nicotine withdrawal symptoms that include depression and exacerbation of underlying psychiatric illness.
3 NRTs are typically discontinued when varenicline is initiated primarily due to increased nausea associated with the combination of these drugs. 5 A small, unpublished trial (n=20) using combined bupropion and varenicline treatment showed good tolerance and effectiveness for control of withdrawal symptoms in high risk smokers. 5 OHP FFS Utilization Analysis Pharmacy and medical encounter claims between 7/1/2006 and 12/31/2007 were reviewed for all patients using varenicline, bupropion, or any NRT. Figure 1 and 2 show claims and ingredient costs per 1,000 and 100 members respectively. Utilization and costs for varenicline have grown significantly over the last 12 months. Figure 1: Prescriptions dispensed Per 1,000 Members Per Month (PMPMx1000) 12 Rx Per 1,000 Members Per Month month/year Bupropion Nicotine Varenicline Figure 2: Ingredient Costs Per 100 Members Per Month (PMPMx100) $120 Cost Per 1,00 Members Per Month $100 $80 $60 $40 $20 $0 month/year Bupropion Nicotine Varenicline Table 1 shows demographics of bupropion, NRT, and varenicline users during the study period. The usage statistics of each agent as shown in table 1 should be interpreted with caution because each has a different base population (i.e. denominator). Bupropion products are reimbursed as FFS for the entire OHP population (i.e. FFS and managed care).
4 Because many NRT products are over-the-counter, the OHP FFS program still pays for dual eligible Medicare recipients. This is reflected in the higher prevalence of Medicare enrollment and the more advanced age of patients receiving this product. Varenicline is strictly an OHP FFS reimbursed agent. In the past 18 months, total expenditures for varenicline have approached $400,000. Current monthly expenditures for varenicline are approximately $36,000. The average cost per 30-day supply of bupropion (brand and generics), NRT (all routes), and varenicline is $89, $71, and $104 respectively. The use of tobacco cessation counseling provided either from the ORQL or billed from a provider was very infrequent. Only 1.3% of varenicline users were registered with the ORQL. 7% of varenicline users received counseling from a billing clinician. However, similar to other things estimated with billing records, this is likely an underestimate of clinic counseling. Table 1: Demographics Bupropion NRT Varenicline n 10,907 2,092 1,793 Total Costs (18 months) $5,607,050 $214,721 $393,753 Cost / 30 Day Supply $89.42 $70.97 $ Avg Age Female 8,008 (73.4%) 1,438 (68.7%) 1,320 (73.6%) Race White 9,777 (89.6%) 1,914 (91.5%) 1,669 (93.1%) Black 328 (3.0%) 31 (1.5%) 8 (0.4%) Native American 259 (2.4%) 92 (4.4%) 61 (3.4%) Hispanic 238 (2.2%) 26 (1.2%) 10 (0.6%) Asian 61 (0.6%) 6 (0.3%) 6 (0.3%) Other/Unknown 244 (2.2%) 23 (1.1%) 39 (2.2%) Quitline Use 14 (0.1%) 45 (2.2%) 24 (1.3%) LTC 307 (2.8%) 257 (12.3%) 45 (2.5%) Medicare 194 (1.8%) 479 (22.9%) 21 (1.2%) Table 2 shows use characteristics of a cohort of varenicline users since initial drug launch in July Over this period, 1,793 unique OHP FFS members started using this drug. Nearly half of using patients had a psychiatric disorder documented using medical claim diagnosis data. Depression and anxiety were the predominate disorders. The average length of therapy for patients starting treatment was 7 weeks (median 4.1 weeks). The recommended therapy for varenicline is one 12-week regimen, with an option for continuation up to 24 weeks. Our analysis suggests 2/3 of users had a length of therapy less than 6 weeks (1,199; 67%). Another 20% used varenicline for another 6 weeks (<12 weeks total treatment) to bring the total 86% of all users. Only 14% of patients starting therapy completed at least 12 weeks of therapy. Concurrent treatment with either bupropion or NRT was relatively uncommon. Conclusions: A very low percentage of smoking cessation users have a record of receiving smoking cessation counseling and very few varenicline users complete the recommended 12 weeks of treatment. A small percentage of patients use varenicline longer than 12 weeks or concurrently with other smoking cessation products. Policy Options: 1. Increase patient and prescriber awareness about Oregon Tobacco Quit Line via a. DUR Newsletter b. Retrospective patient letter to patients with NRT or varenicline highlighting the importance of completing medication regimen and utilizing the quit-line counseling program i. Disadvantage: 2-3 week delay from prescription claim may be too late for effectiveness 2. Require prior authorization of varenicline or NRT to require Oregon Tobacco Quit Line enrollment a. Disadvantage: Medication access and increased administrative cost of PA b. Work with Quit Line to contact PA desk of enrollment? Pharmacist component? 3. Apply 12-week treatment limit and deny claims with concurrent smoking cessation medication use. 4. Allow FFS Medicaid clients to obtain NRT via quit-line In process.
5 Table 2: Varenicline User Characteristics Count Percent n 1,793 Diagnoses Anxiety 373 (20.8%) Bipolar Disorder 174 (9.7%) Depression 472 (26.3%) Insomnia 111 (6.2%) Personality Disorder 46 (2.6%) Post-Traumatic Stress Disorder 177 (9.9%) Schizophrenia 97 (5.4%) Any Psychiatric Diagnosis 867 (48.4%) Therapy characteristics Avg Length of Therapy (wks) 7.0 Count of Patients by Length of Therapy < 6 weeks 1,199 (66.9%) < 12 weeks 1,546 (86.2%) >=12 weeks 247 (13.8%) >=24 weeks 54 (3.0%) >=48 weeks 8 (0.4%) Avg Dose (mg) Mean Modal Dose (mg) Pharmacologic Treatments With bupropion 119 (6.6%) With nicotine drugs 82 (4.6%) Non-Pharmacologic Treatments QuitLine Use 24 (1.3%) Tobacco Counseling 120 (6.7%) Any Tobacco Conseling 141 (7.9%) References: 1. MMWR- "State Medicaid Coverage for tobacco-dependence treatments- United States, 2006".CDC. National Center for Health Statistics. Available at: Accessed 2/1/ New Surgeon General s Report Expands List of Diseases Caused by Smoking. US Dept of Health and Human Services News Release. May 27,2004. Available at 3. (No author). The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives A Clinical Practice Guideline for Treating Tobacco Use and Dependence: A US Public Health Service Report. JAMA. 283(24): , June 28, Fiore Mc, Bailey WC, et al. Treating tobacco use and dependence, clinical practice guideline. U.S. Department of Health and Human Servies. Public Health Services. June available at Accessed Feb 11, Ferry L. Management of high-risk tobacco users: where practice guidelines and clinical judgment meet. Medscape December Available at: Accessed 2/1/ Le Foll, B, George TP; Treatment of tobacco dependence: integrating recent progress into practice. CMAJ 177(11): , Nov Smoking and Tobacco Use. CDC Available at: Accessed 2/4/ McAfee T, Sofian NS, Wilson J, Hindmarsh M. The role of tobacco intervention in population-based health care: a case study. Am J Prev Med 1998;14: Pan W. Proactive telephone counseling as an adjunct to minimal intervention for smoking cessation: a meta-analysis. Health Education Research. 21(3):416-27, June Cummins SE, Bailey L, Campbell S, et al. Tobacco cessation quitlines in North America: a descriptive study. Tobacco Control 2007; 16(suppl 1):i9-i Hollis JF, McAfee TA, et al. The effectiveness and cost effectiveness of telephone counseling and the nicotine patch in a state tobacco quitline. Tobacco Control 2007;16(supp 1):i Yepassis-Zemb rou P. Oregon Tobacco Quit Line Evaluation Report Year 09. Free & Clear, Inc Cahill K, Stead L, Lancaster T. Nnicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007;1:CD Jorenby DE, Leischow SJ, Nides MA, et al. Efficacy of varenicline, an alpha4beta2 nicotine acetylcholine receptor partial agonist vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296: Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: Tonstad S, Tonnesen P, Hajek P, Williams KE, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296(1): Klesges RC, Johson KC, Somes G, Varenicline for Smoking cessation Definite promise, but no panacea. JAMA 2006;296: Chantix NDA. Accessed 2/10/08.
Effective Treatments for Tobacco Dependence
Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for
More information3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine
How can there be a warning regarding concomitant use of varenicline with nicotine replacement therapy yet patients can be on varenicline and smoke concurrently? April 20, 2017 The United States (US) Preventive
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road Des Moines, IA (515) Fax
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road Des Moines, IA 50315 (515) 974-3131 Fax 1-866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Mark Graber, M.D.,
More informationWhat is Quitline Iowa?
CONTENTS: What is Quitline Iowa? 0 A telephone counseling helpline for tobacco-use cessation. Free to all residents of the state of Iowa Open Monday-Thursday 7:00am 12:00am / Friday 7:00am 9:00pm / Saturday
More informationSmoking Cessation: Where Are We Now? Nancy Rigotti, MD
Smoking Cessation: Where Are We Now? Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org OVERVIEW The challenge for
More informationPharmacotherapy for Tobacco Dependence Treatment
Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org
More informationBackground. Abstinence rates associated with varenicline
What are the range of abstinence rates for varenicline for smoking cessation? Do they differ based on treatment duration? Are there any studies utilizing 3-4 months of varenicline treatment? Background
More informationVarenicline Update. Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, Norway
Varenicline Update Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, orway October 23, 2015 Disclosures related to smoking cessation: Pfizer, Mceil, ovartis Binding
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road Des Moines, IA (515) Fax
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road Des Moines, IA 50315 (515) 725-1287 Fax 1-866-626-0216 Bruce Alexander, R.Ph., Pharm.D., BCPP Larry Ambroson, R.Ph. Casey Clor, M.D.
More informationSlide 1. Slide 2. Slide 3. Reducing Tobacco Use and Nicotine Dependence in Clinical Settings. Goals for Today
Slide 1 UNIVERSITY OF HAWAI I CANCER CENTER Reducing Tobacco Use and Nicotine Dependence in Clinical Settings Pebbles Fagan, Ph.D., M.P.H. Associate Professor and Program Director Cancer Prevention and
More informationWanting to Get Pregnant
Continuing Medical Education COPD Case Presentation LEARNING OBJECTIVES Those completing this activity will receive information that should allow them to Assist a patient in developing a quit plan; Advise
More informationMonth/Year of Review: March 2014 Date of Last Review: April 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationTitle: Varenicline for Smoking Cessation. Date: June 4, Context and policy issues:
Title: Varenicline for Smoking Cessation Date: June 4, 2007 Context and policy issues: The prevalence of smoking in Canada continues to drop, according to the 2005 Canadian Tobacco Use Monitoring Survey.
More informationTobacco use assessment, brief counseling,, and quit line referral
Tobacco use assessment, brief counseling,, and quit line referral What is the evidence for tobacco cessation counseling? Tobacco use is the leading cause of preventable death in the US 1 Counseling and
More informationHelping People Quit Tobacco
Helping People Quit Tobacco Peter Selby MBBS, CCFP, MHSc, ASAM Associate Professor, University of Toronto Clinical Director, Addictions Program, CAMH Principal Investigator, OTRU Disclosures! Grants/research
More informationChantix Label Update 2018
Chantix Label Update 2018 Chantix (varenicline) Prescribing Information Chantix Prescribing Info URL and Disclaimer Please refer to the full Prescribing Information on important treatment considerations
More informationVarenicline and Other Pharmacotherapies for Tobacco Dependence
Varenicline and Other Pharmacotherapies for Tobacco Dependence J. Taylor Hays, M.D. Associate Director Nicotine Dependence Center Mayo Clinic 2012 MFMER slide-1 Learning Objectives Understand the mechanism
More informationPharmacologic Therapy for Tobacco Use & Dependence
Pharmacologic Therapy for Tobacco Use & Dependence Thomas Gauvin, MA, TTS Mayo Clinic Nicotine Dependence Center Rochester, MN 2013 MFMER slide-1 Learning Objectives Understand the 7 first line medications
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationEvidence-based Practice
Evidence-based Practice Michael V. Burke, EdD Assistant Professor of Medicine Treatment Program Coordinator Mayo Clinic Nicotine Dependence Center May, 2013 Learning objectives At the end of this presentation
More informationSmoking Cessation. MariBeth Kuntz, PA-C Duke Center for Smoking Cessation
Smoking Cessation MariBeth Kuntz, PA-C Duke Center for Smoking Cessation Objectives Tobacco use at population level Tobacco use and control around the world What works for managing tobacco use Common myths
More informationSMOKING CESSATION IS HARD
POWER TO BREAK THE HOLD OF NICOTINE ADDICTION 1 SMOKING CESSATION IS HARD Most smokers try to quit 5-7 times before they are successful. 2 Why is it so hard to quit? Typical withdrawal symptoms from stopping
More informationHow to help your patient quit smoking. Christopher M. Johnson MD, PhD
How to help your patient quit smoking Christopher M. Johnson MD, PhD Outline Smoking and its effects on IBD CD UC Clinical interventions Pharmacotherapy Resources Outline Smoking and its effects on IBD
More informationYou Can Make a Difference!
You Can Make a Difference! How to help your clients become tobacco free What Does Smoking Cost Us? One study estimates that cost savings of between $1,142 and $1,358 per pregnancy can be achieved for each
More informationTobacco Cessation, E- Cigarettes and Hookahs
Objectives Tobacco Cessation, E- Cigarettes and Hookahs Discuss evidence-based tobacco cessation interventions including pharmacologic options. Review e-cigarette and hookah facts and safety considerations.
More informationHIV and Aging. Making Tobacco Cessation a Priority in HIV/AIDS Services. Objectives. Tobacco Use Among PLWHA
HIV and Aging Making Tobacco Cessation a Priority in HIV/AIDS Services June 27, 2008 Amanda Brown, MPH Ruth Tripp, MPH, RN Objectives To explore existing knowledge of the HIV and smoking connection. To
More informationTobacco Use Dependence and Approaches to Treatment
University of Kentucky UKnowledge Nursing Presentations College of Nursing 11-2011 Tobacco Use Dependence and Approaches to Treatment Audrey Darville University of Kentucky, audrey.darville@uky.edu Chizimuzo
More informationEVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO
EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO Lena Matthias Gray, MSA, CTTS-M University of Michigan MHealthy Tobacco Consultation Service Overview of Tobacco Use The World Health Organization
More informationTobacco & Nicotine: Addiction and Treatment
Tobacco & Nicotine: Addiction and Treatment Tim McAfee, MD, MPH Chief Medical Officer - Free & Clear 206-876-2551 - tim.mcafee@freeclear.com Affiliate Assistant Professor, University of Washington, School
More informationSample Managed Care Organization Survey Questions to Assess Smoking Prevalence and Available Cessation Benefits
Technical Assistance Tool October 2017 Sample Managed Care Organization Survey Questions to Assess Smoking Prevalence and Available Cessation Benefits C ross-agency Medicaid-Public Health teams interested
More informationTobacco treatment for people with serious mental illness (SMI)
Tobacco treatment for people with serious mental illness (SMI) An opportunity to close the mortality gap Massachusetts Mental Health Center 1 National Resource Center for Academic Detailing A compelling
More informationState of Behavioral Health. The Arizona Initiative for Tobacco Free Living in Individuals with Behavioral Health Disorders
Helping People with Mental Health Issues Live Longer Lives without Tobacco The Arizona Initiative for Tobacco Free Living in Individuals with Behavioral Health Disorders Stephen S. Michael, MS Director,
More informationReducing Tobacco Use and Secondhand Smoke Exposure: Quitline Interventions
Reducing Tobacco Use and Secondhand Smoke Exposure: Quitline Interventions Summary Evidence Table Evidence Offering Medication (NRT) through Quitlines and An et al. (2006) Minnesota; smoked five or more
More informationBest Practices in Tobacco Treatment IDN
Best Practices in Tobacco Treatment IDN 6.27.18 Objectives Project SCUM was a plan proposed in 1995 by R. J. Reynolds Tobacco Company (RJR) to sell cigarettes to members of the "alternative lifestyle"
More informationSMOKING CESSATION WORKSHOP. Dr Mark Palayew December
SMOKING CESSATION WORKSHOP Dr Mark Palayew December 5 2016 Conflicts of Interest None Case 1 Mr. T is a 55 year old smoker 2 packs/day He has been smoking continuously since age 16 When he wakes up at
More informationSmoking Cessation: Treating Tobacco Dependence
Smoking Cessation: Treating Tobacco Dependence Pat Folan, RN Center for Tobacco Control Pulmonary Medicine NS-LIJ Health System NYS DOH Tobacco Control Program Treating Tobacco Dependence Center for Tobacco
More informationAddressing Tobacco It Takes a Village
Addressing Tobacco It Takes a Village Charles J. Bentz MD, FACP Medical Director: Tobacco Cessation & Prevention Legacy Health Legacy Health 32 clinics 9500 employees 5 hospitals Children s hospital 320
More informationQUITLINES HELP SMOKERS QUIT
QUITLINES HELP SMOKERS QUIT There is more evidence than ever before that quitlines are effective in helping tobacco users quit and should be part of a comprehensive strategy to lower tobacco use and improve
More informationMEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Smoking Cessation Products LAST REVIEW 5/8/2018 THERAPEUTIC CLASS: Psychiatric Disorders REVIEW HISTORY 5/17, 5/16, 5/15,
More informationThe Science and Practice of Perinatal Tobacco Use Cessation
1 The Science and Practice of Perinatal Tobacco Use Cessation Erin McClain, MA, MPH Catherine Rohweder, DrPH Cathy Melvin, PhD, MPH erin_mcclain@unc.edu Prevention of Tobacco Use and Secondhand Smoke Exposure
More informationPHARMACOTHERAPY OF SMOKING CESSATION
PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure
More informationCT Quitline Annual Report July june 2015
Connecticut Tobacco Use Prevention and Control Program 1 \ ct quitline report - fiscal year 2014-2015 CT Quitline Annual Report July 2014 - june 2015 Prepared for: Connecticut Tobacco Use Prevention and
More informationAddressing Smoking Among Individuals with Behavioral Health Issues
Addressing Smoking Among Individuals with Behavioral Health Issues Carlo C. DiClemente, Ph.D. Director of MDQuit Janine C. Delahanty, Ph.D. Associate Director of MDQuit MHA Annual Conference May 4, 2011
More informationA new model for prescribing varenicline
Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand
More informationTreating Tobacco Use:
Treating Tobacco Use: Optimizing for the Best Outcomes Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org Primary
More informationMedication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019
Medication Management to Aid in Smoking Cessation Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019 1 Learning Objectives: Review the prevalence of tobacco use. Describe tools
More informationALL QUITLINE FACTS: An Overview of the NAQC 2009 Annual Survey of Quitlines
ALL QUITLINE FACTS: An Overview of the NAQC 2009 Annual Survey of The North American Quitline Consortium (NAQC), established in 2004, provides leadership and forums for health departments, quitline service
More informationVarenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?
Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks? Sonal Singh M.D., M.P.H, Johns Hopkins University Presented by: Sonal Singh, MD MPH September 19, 2012 1 CONFLICTS
More informationBASIC SKILLS FOR WORKING WITH SMOKERS
BASIC SKILLS FOR WORKING WITH SMOKERS Course Description Goals and Learning Objectives 55 Lave Ave No, Worcester, MA 01655 www.umassmed.edu/tobacco 2016 Basic Skills for Working with Smokers 1 Table of
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented
More informationTobacco Dependence Treatment: A Resource Guide. Last Update: 06/2013
Tobacco Dependence Treatment: A Resource Guide Last Update: 06/2013 1 Nicotine Replacement Therapy, combined with some form of social support or coaching can double, triple, or even quadruple your chances
More informationEnsuring Medicaid Coverage of Tobacco Cessation
Ensuring Medicaid Coverage of Tobacco Cessation Why is Medicaid Coverage of Tobacco Cessation Important? In 2014, 32 percent of Medicaid enrollees were smokers, compared with 17 percent of the general
More informationRimonabant for treating tobacco dependence
REVIEW Rimonabant for treating tobacco dependence Michael B Steinberg 1,2 Jonathan Foulds 1 1 University of Medicine and Dentistry of New Jersey School of Public Health, Tobacco Dependence Program, New
More informationWE QUIT! Between percent of people living with HIV smoke cigarettes. Quitting is one of the biggest steps you can take to stay healthy.
WE QUIT! Between 60-70 percent of people living with HIV smoke cigarettes. Quitting is one of the biggest steps you can take to stay healthy. People living with HIV/ AIDS who smoke tobacco now lose more
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Policy: Smoking Cessation Products Reference Number: TCHP.PHAR.18002 Effective Date: 01.01.19 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationMy Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.
My Mask KL I keep it all inside Because I d rather The pain destroy me Than everyone else. Anon. 43 K. N. Roy Chengappa, M.D., FRCPC Professor of Psychiatry, University of Pittsburgh School of Medicine,
More informationA systems approach to treating tobacco use and dependence
A systems approach to treating tobacco use and dependence Ann Wendland, MSL Policy Analyst & Cessation Programs Manager NYSDOH Bureau of Tobacco Control ann.wendland@health.ny.gov A systems approach to
More informationSmoking Cessation. Disclosures. Thank You. None
Smoking Cessation Dr. Jamie Kellar; BSc, BScPhm, PharmD Clinician Educator Centre for Addiction and Mental Health Assistant Professor Leslie Dan Faculty of Pharmacy Disclosures None Thank You Several slides
More informationTobacco Dependence Treatment From Neurobiology through Public Policy
Tobacco Dependence Treatment From Neurobiology through Public Policy Mary Ellen Wewers, PhD, MPH, RN Professor Emerita The Ohio State University College of Public Health Disclosures Funding from the National
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.113 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationLearning Objectives 4/3/2018 UP IN SMOKE: NAVIGATING THE CHANGING LANDSCAPE OF SMOKING CESSATION BACKGROUND
UP IN SMOKE: NAVIGATING THE CHANGING LANDSCAPE OF SMOKING CESSATION Richard Dang, PharmD, APh, BCACP Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Rory Kim, PharmD, BCACP Assistant Professor
More informationTobacco cessation outcomes: The case for milestone-based services
Tobacco cessation outcomes: The case for milestone-based services Disa Cornish 1, Ki Park 2, Mitchell Avery 2 ABSTRACT INTRODUCTION This study focuses on a Midwest State s tobacco quitline. The purpose
More informationSmoking Cessation Strategies in 2017
Smoking Cessation Strategies in 2017 Robert Schilz DO, PhD, FCCP Division of Pulmonary, Critical Care and Sleep Medicine Director of Lug Transplantation University Hospitals of Cleveland Case Western University
More informationFax to Quit: A Model for Delivery of Tobacco Cessation Services to Wisconsin Residents
Fax to Quit: A Model for Delivery of Tobacco Cessation Services to Wisconsin Residents Robin J. Perry, BS, CHES; Paula A. Keller, MPH; Dave Fraser, MS; Michael C. Fiore, MD, MPH ABSTRACT Research has shown
More informationPrimary Care Smoking Cessation. GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco
Primary Care Smoking Cessation Dr John McMenamin GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco Target or Tickbox? The Tobacco health target:
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationTobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing
Tobacco Dependence Screening and Treatment in Behavioral Health Settings Prescribing GOAL To build the capacity of prescribing clinicians in behavioral health settings to integrate best practices for prescribing
More informationFast Facts. Morbidity and Mortality (Related to Tobacco Use)
Fast Facts Morbidity and Mortality (Related to Tobacco Use) Tobacco and Disease Tobacco use causes o Cancer o Heart disease o Lung diseases (including emphysema, bronchitis, and chronic airway obstruction)
More informationKeywords: tobacco, cigarette smoke, nicotine, dopamine, smoking cessation, acethylcholine, varenicline (champix )
Review Article and Clinical Experience: ENICLINE (CHAMPIX ) : A BREAKTHROUGH FOR SMOKING CESSATION TREATMENT (An α4ß2 Nicotinic Acethylcholine Receptor Partial Agonist) Askandar Tjokroprawiro Diabetes
More informationSave a Life in 3 Minutes
Save a Life in 3 Minutes Tobacco Cessation for Dental Hygiene Care Produced by Margaret J. Fehrenbach, RDH, MS 1 Not since the polio vaccine has this nation had a better opportunity to make a significant
More informationTobacco smoking is the leading preventable. Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis
Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis Mitchell Nides, PhD; Elbert D. Glover, PhD, FAAHB; Victor I. Reus, MD; Arden G. Christen, DDS, MSA, MA; Barry J. Make,
More informationUpdate on Medications for Tobacco Cessation
Update on Medications for Tobacco Cessation Marc Fishman MD Johns Hopkins University Dept of Psychiatry Maryland Treatment Centers Baltimore MD MDQuit Best Practices Conference Jan 2013 Nicotine Addiction
More informationSave Lives and Money. Help State Employees Quit Tobacco
Save Lives and Money Help State Employees Quit Tobacco 2009 Join These 5 Leading States Cover All the Treatments Your State Employees Need To Quit Tobacco 1 2 Follow these leaders and help your state employees
More information7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5
7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5 2 / 5 3 / 5 7 day quit smoking pdf 7 Your guide to quitting smoking This guide is for smokers who want to quit and stay quit. Just like
More informationReducing Tobacco Use and Secondhand Smoke Exposure: Quitline Interventions
Reducing Tobacco Use and Secondhand Smoke Exposure: Quitline Interventions Summary Evidence Table Evidence Promotional Interventions to Increase Quitline Call Volume An et al. (2006) Design: Minnesota;
More informationSmoking Cessation Services Guidance
Smoking Cessation Services Guidance Alabama Medicaid Tobacco Treatment Coverage Covered Services/Medication 1. Free tobacco cessation counseling is provided through the Alabama Tobacco Quitline. Refer
More informationSmoking Cessation. Hassan Sajjad Pulmonary & Critical Care
Smoking Cessation Hassan Sajjad Pulmonary & Critical Care Objectives Burden of Smoking Health Impacts of Smoking Smoking Cessation Motivational Interviewing Nicotine Replacement Therapy Bupropion Varenicline
More informationResults from the 2013 NAQC Annual Survey of Quitlines
Results from the 2013 NAQC Annual Survey of Quitlines Prepared by: Maria Rudie and Linda Bailey February 2015 Background of Annual Survey Conducted Annually 2004-2006, 2008-2013 Research Partners: 2013
More informationBrief Counselling for Tobacco Use Cessation
Brief Counselling for Tobacco Use Cessation Revised Fall 2011 www.ptcc-cfc.on.ca Overview & Agenda Impact of Tobacco Use Cessation & Comprehensive Tobacco Control Nicotine & Nicotine Delivery Systems Prevalence
More informationProject TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D.
Project TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D. Prevalence of Smoking and Cessation During Pregnancy In 2014, 14% in women with Medicaid coverage versus 3.6% of women with
More informationHow best to get your patients to stop smoking. Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London
How best to get your patients to stop smoking Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London 1 2 Smoking can cause at least 14 different types of cancer 3 Smokers want to stop All smokers
More informationSMOKING CESSATION. Recommendations 5As Approach to Smoking Cessation. Stages of Change Assisting the Smoker. Contributor Dr. Saifuz Sulami.
SMOKING CESSATION 08 Recommendations 5As Approach to Intervention Stages of Change Assisting the Smoker Pharmacotherapy Contributor Dr. Saifuz Sulami Advisor Dr. Audrey Tan 79 nhg_guideline_14102010_1112.indd
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationManagement of Perinatal Tobacco Use
Management of Perinatal Tobacco Use David Stamilio, MD, MSCE Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, UNC School of Medicine Funding for this project is provided in
More informationTREATMENT OF NICOTINE DEPENDENCE
TREATMENT OF NICOTINE DEPENDENCE Introduction Most commonly used substance the world over. Largest cause of preventable death worldwide. Leading causes of smoking related death Cardiovascular diseases
More informationBASIC SKILLS FOR WORKING WITH SMOKERS
BASIC SKILLS FOR WORKING WITH SMOKERS Course Description Goals and Learning Objectives 368 Plantation Street, Worcester, MA 01605 www.umassmed.edu/tobacco 2018 Basic Skills for Working with Smokers 1 Table
More informationSmoking Cessation Strategies: What Works?
Smoking Cessation Strategies: What Works? Andrew M. Busch, Ph.D. Centers For Behavioral and Preventive Medicine The Miriam Hospital Department of Psychiatry and Human Behavior Alpert Medical School of
More informationHow to Design a Tobacco Cessation Insurance Benefit
How to Design a Tobacco Cessation Insurance Benefit All tobacco users need access to a comprehensive tobacco cessation benefit to help them quit. A comprehensive tobacco cessation benefit includes: Nicotine
More informationThese reports were prepared pursuant to directive contained in Section 10 of Senate File 2425 which is listed below:
CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR January 15, 2009 Michael Marshall Secretary of Senate State Capitol LOCAL Mark Brandsgard Chief
More informationUPDATE TREATMENT OF TOBACCO USE DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences UPDATE TREATMENT OF TOBACCO USE DISORDERS MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Remind everyone
More informationSystematic Review Search Strategy
Registered Nurses Association of Ontario Clinical Best Practice Guidelines Program Integrating Tobacco Interventions into Daily Practice (2017) Third Edition Systematic Review Search Strategy Concurrent
More informationSmoking Cessation. May
Smoking Cessation Dear Colleague: The impact of smoking, especially for those with chronic illness, is known and staggering. Currently, there are 46.6 million smokers in the U.S., where tobacco use is
More informationTobacco Cessation Insurance Coverage
Tobacco Cessation Insurance Coverage Why is Insurance Coverage of Tobacco Cessation Important? Tobacco use is the leading cause of preventable death in the U.S., with more than 480,000 deaths each year
More information8/9/18. Objectives. Smoking. Disclosure Statement. The presenters have no real or potential conflicts of interest related to the presentation topic.
Disclosure Statement Multifaceted Smoking Cessation Strategies for Nurse Practitioners The presenters have no real or potential conflicts of interest related to the presentation topic. Dr. Susan Chaney,
More informationTOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS
Learning Objectives TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of
More informationPopulation-level Strategies to Prevent and Reduce Tobacco Use Success and Challenge
Population-level Strategies to Prevent and Reduce Tobacco Use Success and Challenge Harlan R. Juster, Ph.D. Director, Bureau of Tobacco Control New York State Department of health November 6, 2013 Learning
More informationThe 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):
Smoking Cessation Module Tobacco use is the single greatest preventable cause of chronic diseases and premature deaths worldwide. The Canadian Cancer Society reports that tobacco product use is responsible
More informationPUTTING OUT THE ADDICTION:
PUTTING OUT THE ADDICTION: Tobacco Cessation and Prevention Programs INDUSTRY PULSE FROM THE HEALTHCARE INTELLIGENCE NETWORK TM White paper analysis of HIN monthly e-survey results on trends shaping the
More informationTOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS
TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of Pharmacy Learning
More informationImpact of UNC Health Care s Tobacco-Free Hospital Campus Policy on Hospital Employees
Impact of UNC Health Care s Tobacco-Free Hospital Campus Policy on Hospital Employees February 5, 2008 Prepared for: UNC Health Care Prepared by: UNC School of Medicine Nicotine Dependence Program For
More information